Whilst more research is required to determine the contribution of PMCA1 to hypertrophy and HF, there is scope to therapeutically target PMCA1 as a modulator of hypertension to prevent CVD (Little et al., 2016). This evidence concerns the gene ATP2B1 and Hypertension.